Glyxambi® Overview
Patient Profile
Making giant impact in the T2DM patients lives with powerful A1c reduction and a secured Cardio-Renal-Metabolic legacy
Read more
Learn more about powerful HbA1c reduction.
Learn more about CV outcomes with Empagliflozin and Linagliptin
Expert Videos
Video [PC-IN-101414 (September 2021)]
Dr. A. Ramachandran on early intensification
Dr. A. Ramachandran shares his thoughts on early intensification with single…
Video [PC-IN-101306 (July 2021)]
Dr. Mithal on patient selection
Dr. Mithal shares his guidance on patient selection who would derive…
Testimonials of Experts
“Say we divide the cardio-renal continuum in 4 parameters; 3-point MACE, CV death, HF/hHF, renal impairment. Empagliflozin scores 4 on 4, through all the trials done, it shows significant benefit in all 4 parameters. Linagliptin scores 4 on 4 as it shows neutrality in all 4 parameters. Together EMPA + LINA is 8 on 8 for all these parameters”
“Fixed drug combination of Empagliflozin and Linagliptin is proving to be very successful. There is great logic in combining these two drugs. Both of them are not associated with weight gain and both of them are not associated with hypoglycaemia. When you combine Linagliptin with Empagliflozin, even the genital tract infections seem to come down.”
-
CV: Cardiovascular disease.
-
FDC: Fixed dose combination.
-
HbA1c: Glycated haemoglobin.
-
SGLT2i: Sodium-glucose co-transporter 2 inhibitor.
-
DPP4i: Dipeptidyl peptidase 4 inhibitor.
Disclaimer:
-
Glyxambi is not indicated for BP or weight reduction.